A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
published in: Arthritis & Rheumatology
date of publication: 2009-09-01
main subject: placebo, patient, systemic lupus erythematosus, belimumab
Cites articles 39
Date
Title
Article - wd:Q37378350